Daiichi Sankyo And Sarah Cannon Research Institute (Scri) Announced That Extended Follow-Up Data From A Phase 1/2 Trial Of Ds-7300, A Specifically Designed Potential First-In-Class B7-H3 Directed Dxd Antibody Drug Conjugate (Adc), Continues To Show Promising Durable Tumour Response In Patients With Several Types Of Heavily Pretreated Cancers Including Lung, Prostate Or Esophageal Cancer. These Data Were Presented In A Proffered Paper Session (Abstract #453O) At The European Society Of Medical Oncology (#Esmo22) Congress.B7-H3 Is Overexpressed In A Wide Range Of Cancer Types, Including Lung, Prostate And Esophageal, And Its Overexpression Has Been Shown To Correlate With Poor Prognosis In Some Cancers, Making B7-H3 A Promising Therapeutic Target.A Response Rate Of 32% (95% Ci: 24-41) Was Observed With 38 Responses (33 Confirmed; 28%; 95% Ci: 20-37) In 118 Patients With Various Solid Tumours Including Small Cell Lung Cancer (Sclc), Squamous Non-Small Cell Lung Cancer (Nsclc), Metastatic Castration-Resistant Prostate Cancer (Crpc), Esophageal Squamous Cell Carcinoma (Escc), Head And Neck Squamous Cell Carcinoma (Hnscc) Or Endometrial Cancer Receiving Doses Of Ds-7300 Ranging From 4.8 Mg/Kg To 16.0 Mg/Kg.
